SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential breaches of fiduciary duty/or violations of federal and/or state law on behalf of Aquestive Therapeutics, Inc. (NASDAQ: AQST) against certain of its officers and directors.
Earlier this year, a class action complaint was filed against Aquestive Therapeutics. According to the lawsuit, defendants throughout the Class Period made false and misleading statements and failed to disclose that: (1) data included in the Libervant Buccal Film for the management of seizure clusters ("Libervant") New Drug Application ("NDA") submission showed a lower drug exposure level than desired for certain weight groups; (2) the foregoing significantly decreased the Libervant NDA's approval prospects; (3) as a result, it was foreseeable that the U.S. Food and Drug Administration ("FDA") would not approve the Libervant NDA in its current form; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you are a current, long-term shareholder of Aquestive holding shares before August 7, 2019, you may have standing to hold Aquestive harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.
To join this action, you can click or copy and paste the link below: https://www.cognitoforms.com/JohnsonFistel/AquestiveTherapeuticsInc2
Follow us on Twitter: Here
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Investor Relations
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
